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Abstract
Background: Trichlormethiazide, a thiazide diuretic, was introduced in 1960 and remains one of the most
frequently used diuretics for treating hypertension in Japan. While numerous clinical trials have indicated important
side effects of thiazides, e.g., adverse effects on electrolytes and uric acid, very few data exist on serum electrolyte
levels in patients with trichlormethiazide treatment. We performed a retrospective cohort study to assess the
adverse effects of trichlormethiazide, focusing on serum electrolyte and uric acid levels.
Methods: We used data from the Clinical Data Warehouse of Nihon University School of Medicine obtained
between Nov 1, 2004 and July 31, 2010, to identify cohorts of new trichlormethiazide users (n = 99 for 1 mg, n =
61 for 2 mg daily dosage) and an equal number of non-users (control). We used propensity-score matching to
adjust for differences between users and control for each dosage, and compared serum chemical data including
serum sodium, potassium, uric acid, creatinine and urea nitrogen. The mean exposure of trichlormethiazide of 1
mg and 2 mg users was 58 days and 64 days, respectively.
Results: The mean age was 66 years, and 55% of trichlormethiazide users of the 1 mg dose were female. In
trichlormethiazide users of the 2 mg dose, the mean age was 68 years, and 43% of users were female. There were
no statistically significant differences in all covariates (age, sex, comorbid diseases, past drugs, and current
antihypertensive drugs) between trichlormethiazide users and controls for both doses. In trichlormethiazide users of
the 2 mg dose, the reduction of serum potassium level and the elevation of serum uric acid level were significant
compared with control, whereas changes of mean serum sodium, creatinine and urea nitrogen levels were not
significant. In trichlormethiazide users of the 1 mg dose, all tests showed no statistically significant change from
baseline to during the exposure period in comparison with control.
Conclusions: Our study showed adverse effects of decreased serum potassium and increased serum uric acid with
trichlormethiazide treatment, and suggested that a lower dose of trichlormethiazide may minimize these adverse
effects. These findings support the current trend in hypertension therapeutics to shift towards lower doses of
thiazides.
Background
Thiazide diuretics have remained important medications
f o rt h et r e a t m e n to fh y p e r t e n s i o nf o ro v e r5 0y e a r s ,
since they became available in the late 1950s [1,2].
Numerous clinical trials have shown the clinical efficacy
of thiazides, as well as a reduction in cardiovascular
morbidity and mortality, resulting from their blood
pressure (BP)-lowering effect [3-5]. Most complications
of thiazide therapy are related to their adverse-effect
profile. It is well known that thiazides can reduce the
excretion of calcium and uric acid, thereby leading to an
increase in their plasma levels, and that these drugs
increase potassium and magnesium excretion, poten-
tially leading to hypokalemia and hypomagnesemia [6].
Low doses of thiazides, however, are usually tolerated
and have been shown to improve quality-of-life mea-
sures [7]. Thiazides are now more commonly used at
lower doses to minimize the potential harm of adverse
effects. Recent reports thus recommend thiazide diure-
tics as first-line choices for the treatment of essential
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other agents [8,9]. Trichlormethiazide, a thiazide diure-
tic, was introduced in 1960 and remains one of the
most frequently used diuretics for treating hypertension
in Japan [10]. While many studies have shown an
important side effect of thiazides, i.e., adverse effects on
electrolytes, very few data exist on plasma electrolyte
levels in patients with trichlormethiazide treatment. To
clarify whether adverse changes in plasma electrolyte
levels are associated with trichlormethiazide is important
for clinical practice. In this study, we examined changes
in serum electrolyte levels of new users of generally pre-
scribed doses of trichlormethiazide, of 1 mg or 2 mg per
day, and compared them with each respective control
(who had not received trichlormethiazide). We also
examined changes in serum uric acid levels in addition
to serum creatinine and urea nitrogen.
Methods
Data source
This was a retrospective database study using the Nihon
University School of Medicine (NUSM) Clinical Data
Warehouse (CDW), which is a centralized data reposi-
tory that integrates separate databases, such as an order
entry database and a laboratory results database, from
the hospital information systems at three hospitals
affiliated to NUSM. The prescription database in the
CDW contains information from over 0.4 million
patients, and prescribing data are linked longitudinally
to detailed clinical information such as patient demo-
graphics, diagnosis, and laboratory results data.
Study participants
Patients aged over 20 years who had been treated with
antihypertensive agents (thiazide diuretic, b-blocker, cal-
cium channel blocker (CCB), a-blocker, angiotensin-
converting enzyme inhibitor (ACEI), angiotensin II
receptor blocker (ARB), vasodilator or centrally acting
agent) for at least three months between Nov 1, 2004
and July 31, 2010, were identified for the study. Of
28,647 patients who fulfilled the above criteria, we iden-
tified 1404 patients with trichlormethiazide treatment.
We compared new users of trichlormethiazide (1 mg or
2 mg per day) with a propensity-score matched sample
of controls who had not used trichlormethiazide. New
use of an antihypertensive agent was defined as pre-
scription of the study drug, with no use of this drug in
the 90 days preceding the date this prescription was
filled (taken as the index date). We excluded patients
who had received a potassiumo rs o d i u mp r e p a r a t i o n ,
insulin, allopurinol, uricosuric drug or diuretic (loop,
potassium-sparing or thiazide diuretic except for tri-
chlormethiazide) during the study period. We also
excluded patients whose serum creatinine level was
more than 2 mg/dl before the index date. Because tri-
chlormethiazide was often combined with other antihy-
pertensive agents, such as a CCB, ARB or ACEI, we
focused on combination therapy of trichlormethiazide,
a n de x c l u d e dp a t i e n t sw h oh a db e e nt r e a t e dw i t ht r i -
chlormethiazide monotherapy. Consequently, all users of
trichlormethiazide in this study had received combina-
tion therapy with one or more other antihypertensive
agents prior to or on the date trichlormethiazide was
initiated. In addition, patients who had received these
combined agents during at least three months of tri-
chlormethiazide coadministration were selected. The
study cohorts thus included 99 new users of trichlor-
methiazide (1 mg/day) with 99 matched control patients,
and 61 new users of trichlormethiazide (2 mg/day) with
61 matched control patients. The experimental protocol
was approved by the Ethical Committee of Nihon Uni-
versity School of Medicine.
Exposure and measurements
The baseline measurement period (non-exposure period)
was defined as the 60 days before the index date of any
antihypertensive agent. The exposure period (outcome
measurement period) was defined as between 1 and 3
months after the start of trichlormethiazide treatment in
the trichlormethiazide cohort. Blood test data (serum
sodium, potassium, uric acid, creatinine and urea nitro-
gen) were collected for each individual at the date near-
est the index date in the baseline period, and at the date
nearest to three months after the start of trichlormethia-
zide treatment in the exposure period. In trichlor-
methiazide users, the lag-time for starting treatment
with trichlormethiazide from the start of treatment with
other combined antihypertensive agents varied among
individuals. Therefore, the exposure period in the con-
trol cohort was adjusted according to the matched pair
in the trichlormethiazide cohort.
Data elements
For each individual, we collected information of patient
demographics (age and sex), medical history, use of anti-
hypertensive agents or other drugs, and laboratory
results. Medical history included disease information of
cerebrovascular disease (ICD10 codes, I60-I69), ischemic
heart disease (I20-I25), other heart disease (I30-I52),
liver disease (K70-K77), kidney disease (N00-N19), gout
(M10), thyroid gland disorders (E00-E07), hyperlipide-
mia (E78.0-E78.5), and diabetes mellitus (E10-E14),
which had been diagnosed in the 365 days preceding
the first date the prescription of any antihypertensive
agent was filled. This medical history also included the
binary laboratory results of whether urinary protein was
positive or not. We noted current users of antihyperten-
sive agents (b-blocker, CCB, a-blocker, a+b-blocker,
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received them after the index date up to their outcome
measurement. Past users were defined as patients who
received drugs during the 90 days before the index date.
We also noted past users of other drugs than antihyper-
tensive agents, including steroids, lipid-lowering drugs,
oral antihyperglycemic drugs, thyroid drugs and che-
motherapeutic drugs.
Propensity score matching
We used propensity-score matching to reduce bias by
balancing covariates between settings. The propensity
score for each subject is obtained by fitting a logistic
regression model that includes the predictor variable (i.
e., users or non-users) as an outcome and all baseline
covariates in Table 1[11]. We used all these observed
variables regardless of statistical significance. After the
propensity score was constructed, we matched the pro-
pensity score of each patient with diabetes and without
diabetes (a 1:1 match). A nearest-neighbor-matching
algorithm with a “greedy” heuristic was used to match
patients and the logit of their propensity score, with
matching occurring if the difference in the logits of the
propensity scores was less than 0.2 times the standard
deviation (SD) of the scores (caliper width) [12]. This
caliper of 0.2 SD of the logit of propensity score was
suggested by Austin after an extensive simulation study
[13]. We compared the prevalence of all baseline covari-
ates after PS matching using a t-test for continuous vari-
ables and chi-squared tests for categorical data.
Statistical analysis
The t-test was used to compare the differences in means
between the trichlormethiazide use group and the
Table 1 Baseline characteristics after propensity score matching
Characteristic TCM users (1 mg/day) with matched controls TCM users (2 mg/day) with matched controls
Users (n = 99) Controls (n = 99) p-value Users (n = 61) Controls (n = 61) p-value
Exposure days (days, mean ± SD) 57.8 ± 14.8 - 63.9 ± 16.4 -
Age (years, mean ± SD) 65.8 ± 13.5 66.4 ± 11.4 0.7476 67.5 ± 9.9 69.2 ± 11.2 0.3741
Women 54 (55%) 61 (62%) 0.3134 26 (43%) 27 (44%) 0.8551
Medical History
Diabetes mellitus 54 (55%) 57 (58%) 0.6675 42 (69%) 44 (72%) 0.6914
Cerebrovascular diseases 33 (33%) 41 (41%) 0.2399 17 (28%) 11 (18%) 0.1964
Ischemic heart diseases 19 (19%) 21 (21%) 0.7233 12 (20%) 11 (18%) 0.8169
Other heart disease 42 (42%) 35 (35%) 0.3075 34 (56%) 36 (59%) 0.7143
Liver disease 22 (22%) 24 (24%) 0.7364 27 (44%) 25 (41%) 0.7143
Kidney disease 30 (30%) 28 (28%) 0.7548 21 (34%) 17 (28%) 0.4342
Gout 5 (5%) 5 (5%) 1 1 (2%) 1 (2%) 1
Thyroid disorders 27 (27%) 31 (31%) 0.5322 23 (38%) 25 (41%) 0.7109
Hyperlipidemia 59 (60%) 56 (57%) 0.6657 50 (82%) 52 (85%) 0.6248
COPD 5 (5%) 4 (4%) 0.733 5 (8%) 3 (5%) 0.4645
Proteinuria 30 (30%) 32 (32%) 0.7592 22 (36%) 21 (34%) 0.8497
Past drugs
Chemotherapeutic drugs 1 (1%) 0 (0%) 0.3161 3 (5%) 3 (5%) 1
Oral antihyperglycemic drugs 10 (10%) 13 (13%) 0.5058 11 (18%) 15 (25%) 0.3765
Lipid-lowering drugs 30 (30%) 22 (22%) 0.1964 26 (43%) 23 (38%) 0.5796
Steroids 10 (10%) 7 (7%) 0.4467 9 (15%) 5 (8%) 0.2559
Thyroid drugs 3 (3%) 4 (4%) 0.7004 0 (0%) 0 (0%) -
Current antihypertensive drugs
ARB 70 (71%) 67 (68%) 0.6442 35 (57%) 34 (56%) 0.8551
AECI 21 (21%) 23 (23%) 0.7324 14 (23%) 15 (25%) 0.8316
CCB 81 (82%) 83 (84%) 0.7063 44 (72%) 45 (74%) 0.8385
Beta-blocker 14 (14%) 11 (11%) 0.5209 15 (25%) 13 (21%) 0.6668
Alpha+beta-blocker 6(6%) 6 (6%) 1 3 (5%) 3 (5%) 1
Alpha-blocker 8 (8%) 14 (14%) 0.1748 9 (15%) 8 (13%) 0.7938
Alpha-agonist 0 (0%) 0 (0%) - 0 (0%) 0 (0%) -
Vasodilator 0 (0%) 1 (1%) 0.3161 0 (0%) 0 (0%) -
Data are numbers of individuals (%) unless otherwise stated. Abbreviations: TCM, trichlormethiazide; COPD, chronic obstructive pulmonary disease; ARB,
angiotensin II receptor blocker; AECI, angiotensin-converting enzyme inhibitor; CCB, calcium channel blocker.
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P values of less than 0.05 were considered to indicate
statistical significance. All analyses were performed with
SAS software, version 9.2 (SAS Institute, Cary, NC).
Results
Table 1 shows the characteristics of the trichlormethia-
zide cohorts of 1 mg and 2 mg daily dosage and corre-
sponding control cohorts, after propensity-score
matching. There were no statistically significant differ-
ences for all covariates between trichlormethiazide users
and controls for both doses. The mean age was 66
years, and 55% of trichlormethiazide users of the 1 mg
dose were female. In trichlormethiazide users of the 2
mg dose, the mean age was 68 years, and 43% of users
were female. The mean exposure of trichlormethiazide
o f1m ga n d2m gu s e r sw a s5 8d a y sa n d6 4d a y s ,
respectively. In trichlormethiazide users of 1 mg and 2
mg doses, 82% and 72% were currently using a CCB,
and 71% and 57% an ARB, respectively. These findings
suggest that the major counterparts of trichlormethia-
zide combination therapy were CCBs or/and ARBs.
Table 2 shows the results of laboratory test values at
baseline and during the exposure period. There were no
statistically significant differences in the mean values for
all tests between baseline and during the exposure per-
iod in control. In trichlormethiazide users, also, the
mean values for all tests, except the following findings,
showed no significant change between baseline and dur-
ing the exposure period; mean serum sodium level dur-
ing the exposure period was significantly lower than
that at baseline in trichlormethiazide users of the 1 mg
dose, whereas in trichlormethiazide users of the 2 mg
dose, mean serum uric acid level during the exposure
period was significantly higher than that at baseline.
Serum urea nitrogen level also tended to increase. Mean
serum levels for all tests, however, remained within nor-
mal limits during the exposure period in both trichlor-
methiazide users and controls.
Figure 1 shows the changes in laboratory test mean
values during the exposure period compared with base-
line. In trichlormethiazide users of the 1 mg dose, all
tests showed no statistically significant change from
baseline to during the exposure period in comparison
with control, whereas in trichlormethiazide users of the
2 mg dose, the reduction of serum potassium level and
the elevation of serum uric acid level were significant in
comparison with control.
Discussion
In this study, we found that the reduction of serum
potassium level and the elevation of serum uric acid
level in trichlormethiazide users of the 2 mg dose were
significantly greater than those in trichlormethiazide
non-users, but these adverse events did not occur in tri-
chlormethiazide users of the 1 mg dose. Many research-
ers have reported potential adverse events associated
with thiazide therapy, including diuretic-induced hypo-
kalemia and increased serum uric acid [6,14]. Support-
ing these reports, our study demonstrated some adverse
effects, including decreased serum potassium and
increased serum uric acid, with trichlormethiazide, the
same as with other thiazides. Clinical evidence suggests
similar antihypertensive efficacy between low and high
doses, with lower complication rates with low doses
[15,16]. Franse et al demonstrated a trend suggesting
Table 2 Summary of serum chemical data
TCM users (1 mg/day) with matched controls
Laboratory
Test
Users (N = 99) Controls (N = 99)
Mean ± SE (95% CI) Mean ± SE (95% CI)
Urea nitrogen, mmol/L
Baseline 5.83 ± 0.18 (5.47, 6.20) 5.54 ± 0.18 (5.18, 5.90)
Exposure 6.10 ± 0.20 (5.72, 6.51) 5.53 ± 0.17 (5.19, 5.87)
Creatinine, μmol/L
Baseline 71.7 ± 1.9 (67.8, 75.6) 66.3 ± 2.2 (61.9, 70.7)
Exposure 73.2 ± 2.3 (68.6, 77.8) 67.9 ± 2.5 (62.9, 72.9)
Uric acid, μmol/L
Baseline 337.4 ± 8.9 (319.7, 355.1) 316.0 ± 8.1 (300.0, 332.0)
Exposure 349.6 ± 8.5 (332.7, 366.4) 316.8 ± 7.8 (301.3, 332.2)
Sodium, mmol/L
Baseline 142.0 ± 0.3 (141.5, 142.5) 141.8 ± 0.2 (141.3, 142.2)
Exposure 141.1 ± 0.3* (140.5, 141.7) 141.4 ± 0.3 (140.8, 141.9)
Potassium, mmol/L
Baseline 4.24 ± 0.04 (4.17, 4.32) 4.28 ± 0.04 (4.20, 4.35)
Exposure 4.28 ± 0.04 (4.20, 4.36) 4.31 ± 0.04 (4.23, 4.39)
TCM users (2 mg/day) with matched controls
Laboratory
Test
Users (N = 61) Controls (N = 61)
Mean ± SE (95% CI) Mean ± SE (95% CI)
Urea nitrogen, mmol/L
Baseline 6.15 ± 0.24 (5.68, 6.62) 5.66 ± 0.21 (5.24, 6.09)
Exposure 6.80 ± 0.27 (6.25, 7.34) 5.85 ± 0.22 (5.41, 6.29)
Creatinine, μmol/L
Baseline 73.4 ± 3.1 (67.2, 79.6) 68.1 ± 2.2 (63.7, 72.5)
Exposure 77.7 ± 3.5 (70.7, 84.7) 70.3 ± 2.6 (65.1, 75.7)
Uric acid, μmol/L
Baseline 333.7 ± 11.1 (311.5, 355.8) 310.6 ± 9.3 (291.9, 329.1)
Exposure 381.8 ± 11.0** (359.7, 403.9) 327.0 ± 12.0 (303.0, 351.1)
Sodium, mmol/L
Baseline 141.8 ± 0.3 (141.2, 142.3) 141.9 ± 0.3 (141.2, 142.5)
Exposure 141.6 ± 0.3 (141.0, 142.3) 141.6 ± 0.3 (141.0, 142.2)
Potassium, mmol/L
Baseline 4.27 ± 0.06 (4.16, 4.39) 4.32 ± 0.06 (4.21, 4.44)
Exposure 4.13 ± 0.05 (4.03, 4.23) 4.36 ± 0.05 (4.27, 4.45)
*P < 0.05 vs. baseline. **P < 0.01 vs. baseline. Abbreviations: TCM,
trichlormethiazide; SE, standard error; CI, confidence interval.
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greater reduction in serum potassium level and
increased risk of hypokalemia [17]. Hypertension thera-
peutics in recent years, have thus shifted towards lower
doses of thiazides. Because our study was not designed
to compare the cohorts with 1 mg and 2 mg doses of
trichlormethiazide, we cannot strictly conclude whether
the adverse effects on serum potassium and uric acid
are dose-dependent or not. However, our study, showing
an absence of significant adverse effects in the 1 mg
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Page 5 of 8dose of trichlormethiazide users, recommends lower
doses for both trichlormethiazide monotherapy and
combination therapy, the same as for other thiazides.
A few studies have suggested potential adverse effects
of treatment with trichlormethiazide on serum uric acid.
The National Intervention Cooperative Study in Elderly
Hypertensives (NICS-EH) showed that the increase in
serum uric acid level in the trichlormethiazide group
was significantly different from that in the nicardipine
group [18]. Ishimitsu et al showed that serum uric acid
level was significantly higher at the end of combined
treatment with trichlormethiazide than following treat-
ment with olmesartan alone [19]. These studies, how-
ever, showed no significant reduction of serum
potassium level with trichlormethiazide treatment. It is
difficult to accurately compare the findings with regard
to potassium wasting because of variations in study
design and cofounding variables between our study and
those trials. This study focused on combination therapy
and compared trichlormethiazide users and non-users
because a thiazide diuretic is often combined with a
CCB, ARB or ACEI in clinical practice in Japan [10].
When the renin-angiotensin-aldosterone system is
blocked sufficiently, thiazide diuretics enhance BP low-
ering and increase the proportion of patients achieving
goal BP [6,20]. Combination therapy of these agents
with a thiazide diuretic may cancel the adverse effects
associated with diuretic therapy, including diuretic-
induced hypokalemia, hyperglycemia, and increased
s e r u mu r i ca c i d[ 2 1 , 2 2 ] .I nt h i ss t u d y ,w eu s e dp r o p e n -
sity-score matching to balance the population of users
of other combined antihypert e n s i v ea g e n t s ,ap o t e n t i a l
confounding variable, between trichlormethiazide users
and non-users, and thereby found a significant reduction
of serum potassium level in trichlormethiazide users of
the 2 mg dose compared with non-users, whereas in the
comparison between treatment with 2 mg trichlor-
methiazide and baseline, serum potassium level tended
to decrease, but not significantly. This finding may be
biased by various confounders, including other com-
bined agents that would offset the adverse effects of
diuretics.
In this study, serum sodium level during treatment
with trichlormethiazide at the 1 mg dose was lower than
that at baseline, but this negative skew was not seen at
the 2 mg dose. This finding may also be confounded by
other variables because this result was not compared
with that of controls. The discrepancy between 1 mg
and 2 mg users of trichlormethiazide could be explained
in part by differences in the population studied. Thia-
zide-induced hyponatremia is less well characterized. It
usually occurs within 2 weeks after the initiation of
treatment with a thiazide diuretic [23], whereas large
trials using long-term thiazides showed a lack of
generalized reduction in sodium concentration [24].
Risk factors for the development of hyponatremia
include older age, female sex, and low body weight
[23,25]. Previously, the NICE-EH trial showed a signifi-
cant reduction of serum sodium value in the trichlor-
methiazide group in comparison with the nicardipine
group [18]. Trichlormethiazide users in the NICE-EH
trial and our study at the 1 mg dose would be similar
with respect to unmeasured potential confounders that
might differ between 1 mg and 2 mg users of trichlor-
methiazide. These confounding variables may have a
greater impact on the results than trichlormethiazide,
because the reduction of serum sodium level in this
study was not significant in users compared to non-
users of trichlormethiazide. Of the measured variables,
the population with other combined antihypertensive
agents differed between 1 mg and 2 mg users of tri-
chlormethiazide, and may affect the difference in serum
sodium values between the groups. Although it is
unclear whether the reduction in sodium concentration
in our study was induced by trichlormethiazide or/and
other antihypertensive agents, trichlormethiazide is often
used for combination therapy with other antihyperten-
sive drugs in real-world practice. Therefore, when pre-
scribing a thiazide, regular checks of electrolyte levels
should be performed, especially at baseline and within 2
weeks after initiating therapy.
Our study has some limitations. First, the nature of
the observational study involved inherent issues of selec-
tion bias and confounding, which are commonly
encountered in observational studies estimating the
effect of a treatment by comparing outcomes for non-
randomized subjects. Although we used rigorous statisti-
cal methods to balance potential confounding variables
across trichlormethiazide and control users, including
propensity-score matching, their ability to control for
differences was limited to variables for which they were
available or measurable. Nonetheless, the results of well-
designed observational studies (with either a cohort or a
case-control design) were reported not to systematically
overestimate the magnitude of the effects of treatment
as compared with those of randomized-controlled trials
on the same issue [26]. Second, there is also the possibi-
lity of inaccuracy of information in the database (e.g.,
misclassification of exposure and outcome, ascertain-
ment bias, etc). Prescription claims data and medical
records are considered by many to be the gold standard
f o rm e a s u r i n gd r u ge x p o s u r ea n df o rc a p t u r i n gi n t e r -
mediate and final outcomes, respectively [27]. NUSM’s
CDW used in this study may combine the best of both
worlds by linking a prescription database to detailed
medical information, and is suitable for pharmacoepide-
miologic research. Several epidemiological studies exam-
ining the effects of antihypertensive drugs on glucose
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published to date [28,29].
Conclusions
In this study, we observed some adverse effects, includ-
ing decreased serum potassium and increased serum
uric acid, with trichlormethiazide, as with other thia-
zides. These findings support the experience noted in
clinical practice that regular checks of electrolyte levels
should be performed prior to and after thiazide initia-
tion. In addition, our study suggested that a lower dose
of trichlormethiazide may minimize the adverse effects,
supporting the current trend in hypertension therapeu-
tics to shift towards lower doses of thiazides. However,
the findings of our study, based on a non-randomized
design, call for further studies, such as similar analyses
of larger and more recent databases, longitudinal studies
for a long-term period, and randomized clinical trials
for confirmation.
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